Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540229 | 0.92 | HTR6 (0.51) | CA1CA2HTR6CA12CA9 | |
| SCHEMBL6539919 | 0.91 | HTR6 (0.51) | CA1CA2HTR6CA12CA9 | |
| SCHEMBL6540205 | 0.89 | CA1 (0.69) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6541401 | 0.88 | CA1 (0.59) | CA1CA2HTR6CA12CA9 | |
| SCHEMBL6540047 | 0.84 | MEN1 (0.60) | CA1CA2HTR6CA12CA9 | |
| SCHEMBL6541651 | 0.81 | CA1 (0.63) | CA1CA2HTR6CA12CA9 | |
| SCHEMBL6541181 | 0.81 | CA1 (0.58) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6677121 | 0.81 | CA1 (0.50) | CA1CA2CA12CA9CA4 | |
| SCHEMBL3763353 | 0.81 | HTR6 (0.59) | HTR6 | |
| SCHEMBL3763771 | 0.81 | HTR6 (0.59) | HTR6SFRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | CA1 4181/4885CA2 2242/4885HTR6 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.